Evidence map›Paper›PMID 40729203›Full record

ArticleReports (MDPI)2023

Efficacy of Corticosteroids and Intravenous Immunoglobulins in a Patient with Toxic Epidermal Necrolysis Secondary to Sulfadoxine: A Case Report and Literature Review.

Alba Escolà-Rodríguez, Ángel Marcos-Fendian, Carla Bastida, Javier Gil Lianes, Pedro Castro, José Manuel Mascaró, Dolors Soy Muner

Abstract readCase Reports
In one paragraph

Article in Reports (MDPI), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alba Escolà-RodríguezPharmacy Service, Division of Medicines, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-1619-4287
Ángel Marcos-FendianPharmacy Service, Division of Medicines, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-2595-5906
Carla BastidaPharmacy Service, Division of Medicines, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.
Javier Gil LianesDepartment of Dermatology, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-7235-528X
Pedro CastroMedical Intensive Care Unit, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-6118-8970
José Manuel MascaróDepartment of Dermatology, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.
Dolors Soy MunerPharmacy Service, Division of Medicines, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-8128-345X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxic epidermal necrolysis (TEN) is a rare life-threatening mucocutaneous reaction characterized by epidermal detachment. Treatment success relies on early diagnosis, rapid withdrawal of the causative drug and supportive care. However, clinical evidence for therapeutic management and specific treatment is insufficient and controversial. We describe the successful management of a TEN case secondary to sulfadoxine managed in our intensive care unit. The patient presented a generalized exanthema with mucocutaneous detachment affecting 45% of the body surface area, positive Nikolsky sign, perianal enanthema and conjunctival hyperemia. Treatment with intravenous immunoglobulins and corticosteroids was prescribed, as well as calcium folinate to prevent myelotoxicity of the causative drug. In this case, hemodialysis was dismissed due to the low efficiency of this technique in removing the triggering drug. Our case report confirms the efficacy of corticosteroids, IGIV, topical treatment on mucocutaneous lesions and supportive care for the management of TEN secondary to sulfadoxine.

Indexed as

adverse reactionscritical caredermatologic emergenciesdrug-induced toxicodermasulfadoxinetoxic epidermal necrolysis

Identifiers

PMID40729203
PMCPMC12225421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.